Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dusa/Berlex Levulan Actinic Keratoses Recurrence Phase IV Study Planned

Executive Summary

Dusa has committed to a Phase IV study of the actinic keratoses treatment Levulan Kerastick to assess the long-term recurrence rate of treated lesions over a 12-month follow-up period.

You may also be interested in...

Berlex Dermatology's First U.S. Product Will Be Dusa's Levulan

Berlex will begin hiring reps in December for its new U.S. dermatology sales force, which will promote Dusa's Levulan for actinic keratoses.

Dusa Levulan Label Should Disclose Partial Responses, Advisory Panel Says

Dusa Levulan Kerastick labeling which includes a 75% partial lesion clearance response for the actinic keratoses treatment could benefit clinicians and patients, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee decided Nov. 5.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts